Clinical Trial

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a dose-escalation, prospective clinical trial to assess the safety, tolerability, and preliminary therapeutic efficacy of engineered mitochondria expressing specific tumor antigen in patients with advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-13; most recent amendment 2026-03-15.
Trial Details
NCT Number NCT06927297
Lead Sponsor West China Hospital
Conditions Advanced Solid Tumor Malignancies, Advanced Solid Malignancies
Enrollment 12 participants
Start Date 2025-05-09
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-17